A culture for the fermentative production of Massoia lactone comprising an Aureobasidium melanogenum species in a culture medium, wherein the Aureobasidium melanogenum species expresses no functional Aureobasidin A synthase gene mRNA when cultured, the culture medium including KH.sub.2PO.sub.4, Na.sub.2HPO.sub.4, (NH.sub.4).sub.2SO.sub.4, MgSO.sub.4.Math.7H.sub.2O and CaCl.sub.2.Math.2H.sub.2O; at least two trace elements selected from the group consisting of Fe.sup.2+, Cu.sup.2+, Zn.sup.2+ and MoO.sub.4.sup.2−; urea; and a carbon source selected from the group consisting of glucose, mannose, xylose and mixtures thereof, wherein the culture medium has a pH from 5.5 to 6.5.

Provided herein are non-naturally occurring microbial organisms having a pathway for production of (3R)-hydroxybutyl (3R)-hydroxybutyrate, wherein the organism can further include a (R)-1,3-butanediol pathway, a (3R)-hydroxybutyrate pathway, a (3R)-hydroxybutyryl-CoA pathway, an acetoacetate pathway, an acetoacetyl-CoA pathway, a (3R)-hydroxybutyl-ACP pathway, or an acetoacetyl-ACP pathway. Additionally provided are methods and processes for producing and isolating (3R)-hydroxybutyl (3R)-hydroxybutyrate using the microbial organisms, and various compositions having the (3R)-hydroxybutyl (3R)-hydroxybutyrate. Still further provided are methods of treating or preventing a disease, disorder or condition using the (3R)-hydroxybutyl (3R)-hydroxybutyrate produced by the microbial organisms of the invention.

The present invention pertains to a genetically modified saprotroph for the biotechnological production of erythritol and a method for the production of erythritol using said genetically modified saprotroph.

Recombinant expression of influenza virus surface proteins in the fungus Myceliophthora thermophila strain C1 is provided. The recombinant proteins are for use in influenza vaccine compositions.

A microbiological process is provided for the preparation of ursocholic acid, which includes the biotransformation of β-sitosterol in the presence of specific microorganisms.

The present invention relates to endophytes, in particular endophytes associated with plants of the Brachiaria-Urochloa species complex, plants infected with the endophytes, products produced by the endophytes, and related methods.

The present disclosure concerns using transgenic fungus to express recombinant viral antigens. The composition, production, and administration of vaccines comprising those viral antigens also are disclosed. In some embodiments, these viral antigens can be used to formulate a vaccine against Newcastle Disease. These vaccines can be administered, for example, via intramuscular injection.

Methods of production of edible filamentous fungal biomat formulations are provided as standalone protein sources and/or protein ingredients in foodstuffs as well as a one-time use or repeated use self-contained biofilm-biomat reactor comprising a container with at least one compartment and placed within the compartment(s), a feedstock, a fungal inoculum, a gas-permeable membrane, and optionally a liquid nutrient medium.

Provided are an Aspergillus oryzae LGYM4 strain; a red ginseng fermentation product including the strain or a fermentation product thereof: a food composition, a cosmetic composition, a quasi-drug composition, and a pharmaceutical composition, each including the red ginseng fermentation product; a method of preparing the red ginseng fermentation product, the method including the step of performing a fermentation by inoculating the strain into a composition including red ginseng; a red ginseng fermentation product prepared according to the preparation method; and a food composition, a cosmetic composition, a quasi-drug composition, and a pharmaceutical composition, each including the prepared red ginseng fermentation product.

Provided are methods and yeast cultures for producing polyol lipids and polyol lipid compositions.